Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 136.8 Million EUR | 20.09% |
| 2022 | 133.4 Million EUR | 0.45% |
| 2021 | 132.8 Million EUR | 0.15% |
| 2020 | 132.6 Million EUR | -2.14% |
| 2019 | 135.5 Million EUR | 2.42% |
| 2018 | 132.3 Million EUR | -15.63% |
| 2017 | 156.8 Million EUR | 14.04% |
| 2016 | 137.5 Million EUR | -35.39% |
| 2015 | 212.8 Million EUR | 24.15% |
| 2014 | 171.4 Million EUR | 8.96% |
| 2013 | 157.3 Million EUR | 16.57% |
| 2012 | 134.94 Million EUR | 6.93% |
| 2011 | 126.2 Million EUR | 3.79% |
| 2010 | 121.58 Million EUR | -19.4% |
| 2009 | 150.84 Million EUR | -7.74% |
| 2008 | 163.49 Million EUR | 253.4% |
| 2007 | -106.58 Million EUR | -19.23% |
| 2006 | -89.39 Million EUR | -24.57% |
| 2005 | -71.76 Million EUR | -184.33% |
| 2004 | 85.1 Million EUR | -5.28% |
| 2003 | 89.84 Million EUR | -17.58% |
| 2002 | 109 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 25.5 Million EUR | -32.54% |
| 2024 Q1 | 37.8 Million EUR | -49.26% |
| 2023 Q3 | 33.1 Million EUR | 75.13% |
| 2023 Q4 | 74.5 Million EUR | 125.08% |
| 2023 Q2 | 18.9 Million EUR | -44.08% |
| 2023 Q1 | 33.8 Million EUR | -20.66% |
| 2023 FY | 160.2 Million EUR | 20.09% |
| 2022 Q3 | 31.1 Million EUR | -11.14% |
| 2022 Q4 | 42.6 Million EUR | 36.98% |
| 2022 FY | 133.4 Million EUR | 0.45% |
| 2022 Q1 | 31.2 Million EUR | -21.61% |
| 2022 Q2 | 35 Million EUR | 12.18% |
| 2021 Q4 | 39.8 Million EUR | 40.14% |
| 2021 Q1 | 32.3 Million EUR | -9.01% |
| 2021 Q2 | 32.4 Million EUR | 0.31% |
| 2021 Q3 | 28.4 Million EUR | -12.35% |
| 2021 FY | 132.8 Million EUR | 0.15% |
| 2020 FY | 132.6 Million EUR | -2.14% |
| 2020 Q1 | 27.1 Million EUR | -41.21% |
| 2020 Q2 | 38 Million EUR | 40.22% |
| 2020 Q3 | 32 Million EUR | -15.79% |
| 2020 Q4 | 35.5 Million EUR | 10.94% |
| 2019 FY | 135.5 Million EUR | 2.42% |
| 2019 Q4 | 46.1 Million EUR | 45.43% |
| 2019 Q3 | 31.7 Million EUR | 10.45% |
| 2019 Q2 | 28.7 Million EUR | -1.03% |
| 2019 Q1 | 29 Million EUR | -26.4% |
| 2018 FY | 132.3 Million EUR | -15.63% |
| 2018 Q4 | 39.4 Million EUR | 33.11% |
| 2018 Q3 | 29.6 Million EUR | -2.63% |
| 2018 Q2 | 30.4 Million EUR | -7.88% |
| 2018 Q1 | 33 Million EUR | -15.17% |
| 2017 FY | 156.8 Million EUR | 14.04% |
| 2017 Q4 | 38.9 Million EUR | 4.85% |
| 2017 Q3 | 37.1 Million EUR | -15.87% |
| 2017 Q2 | 44.1 Million EUR | 20.16% |
| 2017 Q1 | 36.7 Million EUR | 22.33% |
| 2016 Q2 | 38.8 Million EUR | 3.74% |
| 2016 Q4 | 30 Million EUR | -4.15% |
| 2016 Q3 | 31.3 Million EUR | -19.33% |
| 2016 FY | 137.5 Million EUR | -35.39% |
| 2016 Q1 | 37.4 Million EUR | -34.73% |
| 2015 Q3 | 65.1 Million EUR | 41.21% |
| 2015 Q2 | 46.1 Million EUR | 4.06% |
| 2015 Q1 | 44.3 Million EUR | 4.98% |
| 2015 FY | 212.8 Million EUR | 24.15% |
| 2015 Q4 | 57.3 Million EUR | -11.98% |
| 2014 FY | 171.4 Million EUR | 8.96% |
| 2014 Q3 | 45.7 Million EUR | 6.28% |
| 2014 Q4 | 42.2 Million EUR | -7.66% |
| 2014 Q2 | 43 Million EUR | 6.17% |
| 2014 Q1 | 40.5 Million EUR | -6.03% |
| 2013 Q4 | 43.1 Million EUR | 14.93% |
| 2013 FY | 157.3 Million EUR | 16.57% |
| 2013 Q2 | 39.1 Million EUR | 3.99% |
| 2013 Q1 | 37.6 Million EUR | 14.84% |
| 2013 Q3 | 37.5 Million EUR | -4.09% |
| 2012 FY | 134.94 Million EUR | 6.93% |
| 2012 Q2 | 33.5 Million EUR | -9.46% |
| 2012 Q3 | 31.7 Million EUR | -5.37% |
| 2012 Q4 | 32.74 Million EUR | 3.29% |
| 2012 Q1 | 37 Million EUR | 9.14% |
| 2011 Q2 | 31.9 Million EUR | 8.5% |
| 2011 Q4 | 33.9 Million EUR | 9.36% |
| 2011 Q3 | 31 Million EUR | -2.82% |
| 2011 FY | 126.2 Million EUR | 3.79% |
| 2011 Q1 | 29.4 Million EUR | 89.81% |
| 2010 Q1 | 39.9 Million EUR | 2.18% |
| 2010 Q4 | 15.48 Million EUR | -51.14% |
| 2010 Q2 | 34.5 Million EUR | -13.53% |
| 2010 FY | 121.58 Million EUR | -19.4% |
| 2010 Q3 | 31.7 Million EUR | -8.12% |
| 2009 FY | 150.84 Million EUR | -7.74% |
| 2009 Q4 | 39.04 Million EUR | 12.86% |
| 2009 Q3 | 34.6 Million EUR | -9.9% |
| 2009 Q2 | 38.4 Million EUR | -1.03% |
| 2009 Q1 | 38.8 Million EUR | 0.0% |
| 2008 FY | 163.49 Million EUR | 253.4% |
| 2007 FY | -106.58 Million EUR | -19.23% |
| 2006 FY | -89.39 Million EUR | -24.57% |
| 2005 FY | -71.76 Million EUR | -184.33% |
| 2004 FY | 85.1 Million EUR | -5.28% |
| 2003 FY | 89.84 Million EUR | -17.58% |
| 2002 FY | 109 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ContraFect Corporation | 56.88 Million USD | -140.468% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -57.631% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2681.668% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -52168.403% |
| SQZ Biotechnologies Company | 85.61 Million USD | -59.778% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -4590.98% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -362.897% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -267.192% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -9008.469% |
| Marizyme, Inc. | 19.23 Million USD | -611.025% |
| Genus plc | 147.7 Million USD | 7.38% |
| Pharming Group N.V. | 225.49 Million USD | 39.332% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -6577.389% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -10097.198% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1540.484% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -9151.044% |
| IMV Inc. | 37.7 Million USD | -262.776% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -4802.598% |
| ONE Bio Corp. | 6.44 Million USD | -2022.941% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -59.172% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -35016.001% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -5106.426% |
| Biomind Labs Inc. | 994.18 Thousand USD | -13660.056% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -37.723% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1936.316% |
| Skye Bioscience, Inc. | 13.54 Million USD | -909.777% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -7237.599% |
| Mesoblast Limited | 5.9 Million USD | -2217.858% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 547300.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2613.185% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -754.453% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -7354.655% |
| GB Sciences, Inc. | 1.42 Million USD | -9530.351% |
| MultiCell Technologies, Inc. | 567.42 USD | -24109025.515% |
| Alpha Cognition Inc. | 9.7 Million USD | -1309.495% |
| HST Global, Inc. | 140.9 Thousand USD | -96985.312% |
| CSL Limited | 3.44 Billion USD | 96.034% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 1.37 Million USD | -9872.619% |
| Halberd Corporation | 74.84 Thousand USD | -182685.067% |
| Enzolytics Inc. | 2.17 Million USD | -6176.649% |
| Resverlogix Corp. | 12.71 Million USD | -976.149% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3647.219% |
| argenx SE | 1.53 Billion USD | 91.079% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -13003.448% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -453.51% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -3917.646% |
| Bioxytran, Inc. | 3.82 Million USD | -3481.014% |
| Zenith Capital Corp. | 8.94 Million USD | -1429.688% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -5471.582% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -79662.578% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -7021.639% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 825.34 Million USD | 83.425% |
| Kadimastem Ltd | 2.41 Million USD | -5576.085% |
| Helix BioMedix, Inc. | 1.97 Million USD | -6837.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -7674.15% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -1158.857% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1458.223% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -3002.975% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -3551.487% |
| EV Biologics, Inc. | 531.96 Thousand USD | -25616.123% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -75278.13% |
| Q BioMed Inc. | 3.43 Million USD | -3880.646% |
| LadRx Corporation | 3.81 Million USD | -3488.864% |
| Cell Source, Inc. | 4.32 Million USD | -3062.753% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -32825.852% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -14713.05% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -138.162% |
| Itoco Inc. | 919.14 Thousand USD | -14783.429% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -3127.622% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -12060.973% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -5588.306% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -12125.201% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -8561.764% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1771.341% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -785159.17% |
| NovAccess Global Inc. | 2.46 Million USD | -5445.734% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -543425.766% |
| BioStem Technologies, Inc. | 22.97 Million USD | -495.435% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -62059.78% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -10143.884% |
| Qrons Inc. | 643.67 Thousand USD | -21152.895% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -9535.214% |
| SYBLEU INC | 160.87 Thousand USD | -84934.436% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -6034.862% |
| Rebus Holdings, Inc. | 664 Thousand USD | -20502.41% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -14713.05% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -7431.712% |
| Affymax, Inc. | 39.38 Million USD | -247.332% |
| Mobile Lads Corp. | 554.54 Thousand USD | -24568.828% |
| International Stem Cell Corporation | 5.27 Million USD | -2495.333% |
| CytoDyn Inc. | 18.05 Million USD | -657.559% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -259768.546% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -672367.188% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -277.213% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -8354.883% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -18491.124% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -4297.3% |
| Neutra Corp. | 243.82 Thousand USD | -56006.734% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -683.64% |
| PureTech Health plc | 144.59 Million USD | 5.392% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -567.646% |
| IXICO plc | 4.7 Million USD | -2806.31% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1455.076% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -16.18% |
| CSL Limited | 3.89 Billion USD | 96.486% |
| Cellectis S.A. | 97.32 Million USD | -40.567% |